

Table 1. Comparison of baseline characteristics and examination results between patients undergoing repeat ablation due to AF recurrence and those not undergoing repeat ablation

	Total (n = 2,066)	Repeat ablation due to recurrence (n = 615)	Other patients (n = 1,451)	p-value
Age, years	63.2 ± 11.7	62.7 ± 10.8	63.4 ± 12.1	0.229
Male sex	1,531 (74%)	445 (72%)	1,086 (75%)	0.238
Body weight, kg	65.6 ± 12.7	65.6 ± 13.0	65.6 ± 12.6	0.982
Body mass index, kg/m ²	24.1 ± 3.7	24.1 ± 3.7	24.1 ± 3.7	0.847
Type of AF				0.001
Paroxysmal AF	1,350 (65%)	388 (63%)	962 (66%)	
Persistent AF	529 (26%)	149 (24%)	380 (26%)	
Longstanding persistent AF	187 (9.1%)	78 (13%)	109 (7.5%)	
Symptoms	1,435 (70%)	418 (68%)	1,017 (70%)	0.338
Duration of AF	3.0 ± 4.3	3.6 ± 4.7	2.8 ± 4.1	<0.001
Medications				0.001
Class I	749 (36%)	232 (38%)	517 (36%)	
Class III	246 (12%)	96 (16%)	150 (10%)	
Antiplatelet drug	249 (12%)	86 (14%)	163 (11%)	0.079
DOAC	1,250 (61%)*	294 (48%)	956 (66%)	<0.001
Reduce dose of DOAC	385 (31%)	90 (31%)	295 (31%)	0.936
Comorbidities				
Hypertension	987 (48%)	293 (48%)	694 (70%)	0.938
Diabetes mellitus	306 (15%)	76 (12%)	230 (16%)	0.041
Heart failure	296 (14%)	95 (15%)	201 (14%)	0.344
Stroke	143 (6.9%)	45 (7.3%)	98 (6.8%)	0.645
History of Maze procedure	16 (0.8%)	6 (1.0%)	0 (0.7%)	0.497
Device implantation	68 (3.3%)	21 (3.4%)	47 (3.2%)	0.838
History of thrombus detection before initial ablation	18 (0.9%)	12 (2.0%)	6 (0.4%)	0.001
Recurrence	810 (39%)	615 (100%)	195 (13%)	<0.001
Echocardiographic data				
Left atrial diameter, mm	39.6 ± 6.9	40.4 ± 7.1	39.3 ± 6.7	0.001
Left ventricular ejection fraction, %	60.9 ± 9.8	60.1 ± 9.4	61.2 ± 9.9	0.026
CHADS ₂ score	1.1 ± 1.1	1.0 ± 1.0	1.1 ± 1.1	0.342
CHA ₂ DS ₂ -VASc score	1.9 ± 1.5	1.9 ± 1.5	2.0 ± 1.6	0.172

HAS-BLED score	1.3 ± 1.0	1.3 ± 1.1	1.3 ± 1.0	0.702
Laboratory data				
Creatinine clearance, mL/min	82.9 ± 32.5	83.6 ± 31.7	82.6 ± 32.8	0.544
B-type natriuretic peptide levels, pg/dL	54 (24–118)	61 (29–122)	51 (21–117)	0.003
Evaluation of the LA thrombus before first ablation				
TEE	2,013 (97%)	598 (97%)	1,415 (98%)	0.710
Contrast enhanced CT image	1,926 (93%)	576 (94%)	1,350 (93%)	0.609
ICE	5 (0.2%)	0 (0%)	5 (0.3%)	0.330
Both TEE and CT image	1,874 (91%)	559 (91%)	1,315 (91%)	0.848
At least one modality in the TEE, CT image, or ICE	2,066 (100%)	615 (100%)	1,451 (100%)	0.999
None	0 (0%)	0 (0%)	0 (0%)	0.999
Ablation procedures				
Radiofrequency ablation	1,589 (77%)	539 (88%)	1,050 (72%)	<0.001
Pulmonary vein isolation	2,044 (99%)	610 (99%)	1,434 (99%)	0.468
Cavotricuspid isthmus ablation	1,453 (70%)	470 (76%)	983 (68%)	<0.001
LA leaner ablation	605 (29%)	202 (33%)	403 (28%)	0.021
Mitral isthmus ablation	367 (18%)	133 (22%)	234 (16%)	0.003
SVC isolation	104 (5.0%)	47 (7.6%)	57 (3.9%)	<0.001
CFAE and other ablations	415 (20%)	113 (18%)	302 (21%)	0.206
Procedure time	179.9 ± 55.9	190.3 ± 63.4	175.4 ± 51.6	<0.001

*The DOACs included apixaban in 512 patients, rivaroxaban in 276, dabigatran in 256, and edoxaban in 206. AF, atrial fibrillation; CT, computed tomography; DOAC, direct oral anticoagulant; ICE, intracardiac echocardiography; LA, left atrium; SVC, superior vena cava; CFAE, complex fractionated atrial electrograms; TEE, transesophageal echocardiography.